Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream

Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream

Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The...

Full description

Bibliographic Details
Main Authors: Luana Calabrò, Giuseppe Bronte, Federica Grosso, Luigi Cerbone, Angelo Delmonte, Fabio Nicolini, Massimiliano Mazza, Anna Maria Di Giacomo, Alessia Covre, Maria Fortunata Lofiego, Lucio Crinò, Michele Maio
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
pleural mesothelioma
immunotherapy
immune checkpoint inhibitors
adoptive cell therapy
epigenetic drugs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1333661/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1333661/full

Similar Items